ABVC BioPharma Executes A Global Licensing Term Sheet For Oncology/Hematology Products, Expecting Licensing Income Of $55M And Royalties Of Up To $50M
Portfolio Pulse from Benzinga Newsdesk
ABVC BioPharma, Inc. (NASDAQ:ABVC) has executed a term sheet with OncoX BioPharma, Inc. for the global licensing of its Oncology/Hematology products, expecting to receive $55M in licensing income and up to $50M in royalties. The deal includes clinical trial, registration, manufacturing, supply, and distribution rights for ABVC's pipeline, with the US FDA approving four INDs for various cancers. The partnership aims to leverage both companies' strengths to drive innovation and create value in the Oncology/Hematology sector.
April 10, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ABVC BioPharma enters a significant licensing agreement with OncoX BioPharma for its Oncology/Hematology pipeline, expecting substantial licensing income and royalties.
The licensing agreement with OncoX BioPharma represents a significant milestone for ABVC BioPharma, potentially leading to substantial financial gains and a stronger position in the Oncology/Hematology market. The expected licensing income and royalties signal a positive financial outlook for ABVC, likely leading to increased investor confidence and a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100